Advertisement
U.S. markets close in 1 hour 23 minutes

Cocrystal Pharma, Inc. (COCP)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Visitors trend2W10W9M
1.5080-0.0320 (-2.09%)
As of 02:31PM EDT. Market open.
Full screen
Add
Comparison
Indicators
Technicals
Corporate Events
Mountain
DrawTable View
Settings
AllAllFavoritesTextStatisticsTechnicalsFibonacciMarkingsLines
Loading interactive chart...
1D
Date Range
Interval:
1 min
  • Zacks Small Cap Research

    COCP: Topline Data for Influenza A and Dual Coronavirus/Norovirus Programs Expected in 2024; Model Revision Leads to Valuation of $6 Per Share…

    By David Bautz, PhD NASDAQ:COCP READ THE FULL COCP RESEARCH REPORT Business Update Update on Influenza Program Cocrystal Pharma, Inc. (NASDAQ:COCP) is developing CC-42344, a broad spectrum inhibitor of pandemic and seasonal strains of influenza A. CC-42344 targets subunit PB2, which along with PA and PB1 forms the RNA-dependent RNA polymerase. This polymerase is essential for viral replication in

  • GlobeNewswire

    Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

    FDA feedback following the Company’s submission of a Pre-IND briefing package improves clarity on regulatory requirements for Phase 2b influenza A clinical trial with oral CC-42344, a broad-spectrum PB2 inhibitorTopline data expected in 2024 from Phase 2a influenza A human challenge study and Phase 1 study with oral CDI-988, the first potential dual coronavirus-norovirus oral antiviralInitiation of Phase 1 study expected in 2024 with inhaled CC-42344, a potential influenza treatment and post-exp

  • GlobeNewswire

    Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A

    Feedback provides greater clarity on regulatory requirements for planned Phase 2b trial BOTHELL, Wash., March 19, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces it has received Pre-Investigational New Drug (Pre-IND) feedback from the U.S. Food and Drug Administration (FDA) regarding CC-42344 as a potential oral treatment for pandemic and seasonal influenza A. A Pre-IND review provides the opportunity to obtain FDA guidance and clarificatio